312 related articles for article (PubMed ID: 23261227)
41. False-negative rate after positron emission tomography/computer tomography scan for mediastinal staging in cI stage non-small-cell lung cancer.
Gómez-Caro A; Boada M; Cabañas M; Sanchez M; Arguis P; Lomeña F; Ramirez J; Molins L
Eur J Cardiothorac Surg; 2012 Jul; 42(1):93-100; discussion 100. PubMed ID: 22290911
[TBL] [Abstract][Full Text] [Related]
42. Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma.
Huang CT; Yen RF; Cheng MF; Hsu YC; Wei PF; Tsai YJ; Tsai MF; Shih JY; Yang CH; Yang PC
Med Oncol; 2010 Mar; 27(1):9-15. PubMed ID: 19130320
[TBL] [Abstract][Full Text] [Related]
43. Toward personalized medicine of lung cancer: response to nontargeted therapy in invasive pulmonary adenocarcinoma as a function of tumor cell differentiation.
Hartel PH; Hartel JV; Fanburg-Smith JC; Gilmore RW; Fleming D; Barnett S; Mudry R; Parker JE
Int J Surg Pathol; 2013 Jun; 21(3):224-8. PubMed ID: 23637254
[TBL] [Abstract][Full Text] [Related]
44. MET and EGFR mutations identified in ALK-rearranged pulmonary adenocarcinoma: molecular analysis of 25 ALK-positive cases.
Boland JM; Jang JS; Li J; Lee AM; Wampfler JA; Erickson-Johnson MR; Soares I; Yang P; Jen J; Oliveira AM; Yi ES
J Thorac Oncol; 2013 May; 8(5):574-81. PubMed ID: 23449277
[TBL] [Abstract][Full Text] [Related]
45. Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma.
Kim MH; Shim HS; Kang DR; Jung JY; Lee CY; Kim DJ; Lee JG; Bae MK; Kim HR; Lim SM; Kim EY; Park JS; Chung KY; Kim HJ; Kim JH; Cho BC
Lung Cancer; 2014 Mar; 83(3):389-95. PubMed ID: 24462463
[TBL] [Abstract][Full Text] [Related]
46. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
47. (18)F-fluorodeoxyglucose positron emission tomography versus computed tomography in predicting histopathological response to epidermal growth factor receptor-tyrosine kinase inhibitor treatment in resectable non-small cell lung cancer.
van Gool MH; Aukema TS; Schaake EE; Rijna H; Codrington HE; Valdés Olmos RA; Teertstra HJ; van Pel R; Burgers SA; van Tinteren H; Klomp HM
Ann Surg Oncol; 2014 Sep; 21(9):2831-7. PubMed ID: 24845729
[TBL] [Abstract][Full Text] [Related]
48. [Diagnostic value of (18)F-FDG PET/CT imaging plus serum tumor marker assays for pulmonary lesions and clinical significance of SUVmax].
Zhang TM; Zhang LM; Liu Y; Zhang ZF; Wang CL
Zhonghua Yi Xue Za Zhi; 2012 Nov; 92(41):2901-4. PubMed ID: 23328236
[TBL] [Abstract][Full Text] [Related]
49. Standardized uptake value differences between primary and metastatic lesions in ¹⁸F-FDG PET/CT of patients with lung cancer.
Kosaka N; Tsuchida T; Tsuji K; Shimizu K; Kimura H
Acta Radiol; 2015 Nov; 56(11):1329-35. PubMed ID: 25398775
[TBL] [Abstract][Full Text] [Related]
50. Histological subtypes of lung adenocarcinoma have differential ¹⁸F-fluorodeoxyglucose uptakes on the positron emission tomography/computed tomography scan.
Chiu CH; Yeh YC; Lin KH; Wu YC; Lee YC; Chou TY; Tsai CM
J Thorac Oncol; 2011 Oct; 6(10):1697-703. PubMed ID: 21869716
[TBL] [Abstract][Full Text] [Related]
51. Clinical staging of patients with early esophageal adenocarcinoma: does FDG-PET/CT have a role?
Cuellar SL; Carter BW; Macapinlac HA; Ajani JA; Komaki R; Welsh JW; Lee JH; Swisher SG; Correa AM; Erasmus JJ; Hofstetter WL
J Thorac Oncol; 2014 Aug; 9(8):1202-6. PubMed ID: 25157774
[TBL] [Abstract][Full Text] [Related]
52. Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma.
Paik JH; Choi CM; Kim H; Jang SJ; Choe G; Kim DK; Kim HJ; Yoon H; Lee CT; Jheon S; Choe JY; Chung JH
Lung Cancer; 2012 Jun; 76(3):403-9. PubMed ID: 22129856
[TBL] [Abstract][Full Text] [Related]
53. EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR.
Wu SG; Kuo YW; Chang YL; Shih JY; Chen YH; Tsai MF; Yu CJ; Yang CH; Yang PC
J Thorac Oncol; 2012 Jan; 7(1):98-104. PubMed ID: 22124476
[TBL] [Abstract][Full Text] [Related]
54. Cytomorphological features of ALK-positive lung adenocarcinomas: psammoma bodies and signet ring cells.
Pareja F; Crapanzano JP; Mansukhani MM; Bulman WA; Saqi A
Cancer Cytopathol; 2015 Mar; 123(3):162-70. PubMed ID: 25557162
[TBL] [Abstract][Full Text] [Related]
55. Prognostic Value of Baseline 18F-FDG PET/CT Functional Parameters in Patients with Advanced Lung Adenocarcinoma Stratified by EGFR Mutation Status.
Wang D; Zhang M; Gao X; Yu L
PLoS One; 2016; 11(6):e0158307. PubMed ID: 27336755
[TBL] [Abstract][Full Text] [Related]
56. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization.
Paik JH; Choe G; Kim H; Choe JY; Lee HJ; Lee CT; Lee JS; Jheon S; Chung JH
J Thorac Oncol; 2011 Mar; 6(3):466-72. PubMed ID: 21258247
[TBL] [Abstract][Full Text] [Related]
57. Correlation of EGFR or KRAS mutation status with 18F-FDG uptake on PET-CT scan in lung adenocarcinoma.
Takamochi K; Mogushi K; Kawaji H; Imashimizu K; Fukui M; Oh S; Itoh M; Hayashizaki Y; Ko W; Akeboshi M; Suzuki K
PLoS One; 2017; 12(4):e0175622. PubMed ID: 28422979
[TBL] [Abstract][Full Text] [Related]
58. [Clinicopathologic correlation and ALK rearrangement in adenocarcinoma of lung].
Liu P; Wang C; Wu S; Gao J; Zeng X
Zhonghua Bing Li Xue Za Zhi; 2014 Apr; 43(4):241-5. PubMed ID: 24915814
[TBL] [Abstract][Full Text] [Related]
59. Cytology specimens offer an effective alternative to formalin-fixed tissue as demonstrated by novel automated detection for ALK break-apart FISH testing and immunohistochemistry in lung adenocarcinoma.
Rosenblum F; Hutchinson LM; Garver J; Woda B; Cosar E; Kurian EM
Cancer Cytopathol; 2014 Nov; 122(11):810-21. PubMed ID: 25099128
[TBL] [Abstract][Full Text] [Related]
60. 18F-FDG uptake by metastatic axillary lymph nodes on pretreatment PET/CT as a prognostic factor for recurrence in patients with invasive ductal breast cancer.
Song BI; Lee SW; Jeong SY; Chae YS; Lee WK; Ahn BC; Lee J
J Nucl Med; 2012 Sep; 53(9):1337-44. PubMed ID: 22870824
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
